Related Experiment Video
Updated: Jun 17, 2026
09:45
Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
Published on: May 18, 2021
[Monoclonal antibodies for treating infectious diseases]
Christine Klinguer-Hamour1, Véronique Caussanel, Alain Beck
1Centre d'immunologie Pierre Fabre, 5, avenue Napoléon III, BP 60497, 74160 Saint-Julien en Genevois, France. christine.klinguer.hamour@pierre-fabre.com
Medecine Sciences : M/S
|December 29, 2009
Summary
Monoclonal antibodies (mAbs) show promise beyond cancer treatment, with growing development for infectious diseases due to antibiotic resistance and emerging threats. Combining these biologic drugs with small molecule therapies offers new treatment avenues.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Context:
- Monoclonal antibodies (mAbs) are highly specific biologic drugs, traditionally used for cancers and immunological disorders.
- The rise of antibiotic resistance, novel viral diseases, and bioterrorism necessitates new anti-infective strategies.
- Over twenty clinical trials are underway evaluating the safety and efficacy of anti-infective mAbs.
Purpose:
- To explore the expanding role of monoclonal antibodies (mAbs) in combating infectious diseases.
- To highlight the potential of combining anti-infective mAbs with small molecule drugs for enhanced therapeutic outcomes.
Summary:
- Monoclonal antibodies (mAbs) are increasingly being developed as anti-infective agents, moving beyond their traditional applications.
- The development pipeline includes numerous clinical trials assessing the efficacy of these targeted therapies against resistant bacteria, viruses, and bioterrorism agents.
- Synergistic treatment approaches combining mAbs with small molecule drugs are emerging as a promising strategy for managing infectious diseases.
Impact:
- Anti-infective monoclonal antibodies represent a significant advancement in addressing global health challenges like antibiotic resistance and emerging pandemics.
- Combination therapies involving mAbs and small molecules could revolutionize the treatment of infectious diseases, offering improved efficacy and broader applicability.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:36Humoral Immune Responses
Overview
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...